Melanotan-1

The speaker concludes that stacking MT-1 with astaxanthin should not be a concern because the two compounds operate through completely different mechanisms and do not compete for the same receptor or overlap in any known pathway. The combination may offer complementary coverage — MT-1 driving melanin synthesis and astaxanthin providing carotenoid antioxidant support. No specific dosages are mentioned for either compound.

According to the speaker, MT-1 does not have any well-established drug interactions. This characterization is offered as context for evaluating the safety of stacking MT-1 with other compounds. No dosage information is provided in this segment.

MT-1 (Melanotan-1) works by activating melanocytes to drive melanin synthesis, producing a tan effect from the inside out. This mechanism also confers some degree of photoprotection. The speaker presents this as the established pharmacological basis for MT-1's action.

This peptide-focused channel contrasts the two: MT-1 (afamelanotide, branded Scenesse) is FDA-approved for erythropoietic protoporphyria, works predominantly through MC1R, preferentially boosts UV-absorbing eumelanin over carcinogenic pheomelanin, and has a favorable safety profile with no evidence at this point of increased melanoma risk. MT-2 is a shortened cyclic analog with broader affinity for MC3, MC4 and MC5, which is why users report libido and appetite effects alongside tanning, and it is that broad affinity plus multiple case reports of melanocytic changes and melanomas that make it the higher-risk cousin.